Drug name - Zeposia

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8796318 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(6 years from now)

US8481573 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(6 years from now)

CN102118972A CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

CN102118972B CELGENE INTL Regulator Of Sphingosine Phosphate Receptor
May, 2029

(6 years from now)

IN305486B CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

IN201818041445A CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

IN396031B CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

EP2913326B1 CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

EP2913326A1 CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

EP2291080A4 CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

EP2291080A1 CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

EP2291080B1 CELGENE INTL Novel Modulators Of Sphingosine Phosphate Receptors
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9382217 CELGENE INTL Modulators of sphingosine phosphate receptors May, 2029

(6 years from now)

US10239846 CELGENE INTL Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis Nov, 2030

(8 years from now)

Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the treatment of moderately to severely active ulcerative colitis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.23MG BASE CAPSULE;ORAL Prescription
EQ 0.46MG BASE CAPSULE;ORAL Prescription
EQ 0.92MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.